About InVivoSIM anti-human GPNMB (Glembatumumab Biosimilar) This non-therapeutic biosimilar antibody utilizes the same variable regions as the therapeutic antibody Glembatumumab, making it ideal for research use. Glembatumumab is a fully human IgG2 monoclonal antibody that targets glycoprotein non-metastatic melanoma protein B (GPNMB), a transmembrane glycoprotein overexpressed in various cancers, including triple-negative breast cancer (TNBC), melanoma, glioblastoma, and osteosarcoma. GPNMB is associated with tumor progression, metastasis, and poor prognosis. In therapeutic applications, Glembatumumab is conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) to form the antibody-drug conjugate (ADC) Glembatumumab vedotin. This ADC binds to GPNMB-expressing tumor cells, is internalized, and releases MMAE intracellularly, leading to cell death. However, this biosimilar is unconjugated and formulated for non-therapeutic research use only, making it an excellent tool for studying GPNMB biology, tumor immunology, and the development of GPNMB-targeted therapies. InVivoSIM anti-human GPNMB (Glembatumumab Biosimilar) Specifications IsotypeHuman IgG2, κ Recommended Isotype Control(s)RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman GPNMB Reported ApplicationsFunctional assays Flow cytometry ELISA Immunohistochemistry Western blot FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
